Gemifloxacin mesylate (SB-265805S)
(Synonyms: 甲磺酸吉米沙星; SB-265805S; LB-20304a) 目录号 : GC33921
A fluoro
Cas No.:210353-53-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Gemifloxacin is a fluoroquinolone antibiotic that is effective against C. pneumoniae and M. tuberculosis (MIC50s = 0.25 and 8 ?g/ml, respectively).1,2 Quinolones, including gemifloxacin, inhibit bacterial DNA gyrase and other topoisomerases.3,4 Formulations containing gemifloxacin are useful against respiratory tract infections, particularly community-acquired pneumonia and tuberculosis.1,5,6
1.Hammerschlag, M.R., Roblin, P.M., and Bébéar, C.M.Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogensJ. Antimicrob. Chemother.48(Topic T1)25-31(2001) 2.Ruiz-Serrano, M.J., Alcalá, L., Martínez, L., et al.In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugsAntimicrob. Agents Chemother.44(9)2567-2568(2000) 3.Collin, F., Karkare, S., and Maxwell, A.Exploiting bacterial DNA gyrase as a drug target: Current state and perspectivesAppl. Microbiol. Biotechnol.92(3)479-497(2011) 4.Weigel, L.M., Anderson, G.J., and Tenover, F.C.DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilisAntimicrob. Agents Chemother.46(8)2582-2587(2002) 5.Grossman, R.F., Hsueh, P.-R., Gillespie, S.H., et al.Community-acquired pneumonia and tuberculosis: Differential diagnosis and the use of fluoroquinolonesInt. J. Infect. Dis.1814-21(2014) 6.Pranger, A.D., Alffenaar, J.W.C., and Aarnoutse, R.E.Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: A pharmacokinetic and pharmacodynamic approachCurr. Pharm. Des.17(27)29002-29930(2011)
| Cas No. | 210353-53-0 | SDF | |
| 别名 | 甲磺酸吉米沙星; SB-265805S; LB-20304a | ||
| Canonical SMILES | O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CC(CN)/C(C4)=N/OC)=N3)C1=O)O.CS(=O)(O)=O | ||
| 分子式 | C19H24FN5O7S | 分子量 | 485.49 |
| 溶解度 | DMSO : ≥ 43 mg/mL (88.57 mM) | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0598 mL | 10.2989 mL | 20.5977 mL |
| 5 mM | 0.412 mL | 2.0598 mL | 4.1195 mL |
| 10 mM | 0.206 mL | 1.0299 mL | 2.0598 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Structural elucidation of Gemifloxacin mesylate degradation product
Biomed Chromatogr 2016 Mar;30(3):459-65.PMID:26205148DOI:10.1002/bmc.3569.
Gemifloxacin mesylate (GFM), chemically (R,S)-7-[(4Z)-3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid methanesulfonate, is a synthetic broad-spectrum antibacterial agent. Although many papers have been published in the literature describing the stability of fluorquinolones, little is known about the degradation products of GFM. Forced degradation studies of GFM were performed using radiation (UV-A), acid (1 mol L(-1) HCl) and alkaline conditions (0.2 mol L(-1) NaOH). The main degradation product, formed under alkaline conditions, was isolated using semi-preparative LC and structurally elucidated by nuclear magnetic resonance (proton - (1) H; carbon - (13) C; correlate spectroscopy - COSY; heteronuclear single quantum coherence - HSQC; heteronuclear multiple-bond correlation - HMBC; spectroscopy - infrared, atomic emission and mass spectrometry techniques). The degradation product isolated was characterized as sodium 7-amino-1-pyrrolidinyl-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate, which was formed by loss of the 3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl ring and formation of the sodium carboxylate. The structural characterization of the degradation product was very important to understand the degradation mechanism of the GFM under alkaline conditions. In addition, the results highlight the importance of appropriate protection against hydrolysis and UV radiation during the drug-development process, storage, handling and quality control.
Gemifloxacin mesylate (GFM): dissolution test based on in vivo data
Drug Dev Ind Pharm 2015 Apr;41(4):567-72.PMID:24517572DOI:10.3109/03639045.2014.884128.
Gemifloxacin mesylate (GFM) is a synthetic, broad-spectrum, fluoroquinolone antibacterial agent. It is different from other class members because it achieves adequate plasma concentrations to inhibit both topoisomerase IV and gyrase. The aim of this study was to develop and validate a dissolution test for GFM in coated tablets, using a simulated absorption profile based on in vivo data obtained from the literature. The fraction and percentage of the dose absorbed were calculated using model-dependent Loo-Riegelman approach for two compartments. The best in vitro dissolution profile was obtained using 900 mL of pH 6.0 phosphate buffer as a dissolution medium at 37 °C ± 0.5 °C and paddles at 50 rpm. The in vitro dissolution samples were analyzed using a liquid chromatography method, and the validation was performed according to USP 34 (2011). The method showed specificity, precision, accuracy, robustness and linearity. Under these conditions, a level-A in vitro-in vivo correlation was suggested (r = 0.9926). The prediction errors were calculated to determine the validity and accuracy of the suggested correlation. The dissolution test can be used to evaluate the dissolution profile of GFM-coated tablets and minimize the number of bioavailability studies as part of new formulation development.
Spectrofluorimetric analysis of Gemifloxacin mesylate in pharmaceutical formulations
Luminescence 2014 Mar;29(2):127-31.PMID:23681953DOI:10.1002/bio.2515.
A simple, rapid and highly sensitive spectrofluorimetric method was developed for determination of Gemifloxacin mesylate (GFX) in tablets. The method is based on measuring the native fluorescence of GFX in isopropanol at 400 nm after excitation at 272 nm. The fluorescence-concentration plot was rectilinear over the range of 0.01-0.50 µg/mL with a lower detection limit of 1.19 ng/mL and quantification limit of 3.6 ng/mL. The method was fully validated and successfully applied to the determination of GFX tablets with an average percentage recovery of 99.65 ± 0.532. The method was extended to the stability study of GFX. The drug was exposed to acidic, alkaline, oxidative and photolytic degradation according to International Conference on Harmonization guidelines. The rate of GFX degradation was found at its highest in acidic conditions, and in its lowest in the neutral one. However, it was stable under dry heat and photolytic degradation conditions.
Determination of gemifloxacin in different tissues of rat after oral dosing of Gemifloxacin mesylate by LC-MS/MS and its application in drug tissue distribution study
J Pharm Biomed Anal 2010 Jun 5;52(2):216-26.PMID:20092976DOI:10.1016/j.jpba.2009.12.019.
A simple, sensitive and specific liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated to evaluate the accumulation of gemifloxacin in different tissues of Wister albino rat. The analytical method consists of the homogenization of tissues followed by simple liquid-liquid extraction and determination of gemifloxacin by an LC-MS/MS. The analyte was separated on a Peerless basic C(18) column (33 mm x 4.6 mm, 3 microm) with an isocratic mobile phase of methanol-water containing formic acid (1.0%, v/v) (9:1, v/v) at a flow rate of 0.6 ml/min. The MS/MS detection was carried out by monitoring the fragmentation of m/z 390.100-->372.100 for gemifloxacin and m/z 332.100-->314.200 for ciprofloxacin (internal standard; IS) on a triple quadrupole mass spectrometer. The validated method was accurate, precise and rugged with good linearity in all tissue homogenates. The accuracy and precision value obtained from six different sets of quality control samples of all tissues and serum analyzed in separate occasions within 91.833-102.283% and 0.897-5.291%, respectively. The method has been successfully applied to tissue distribution studies of gemifloxacin. The present study demonstrates that the highest tissue concentration of gemifloxacin was obtained in lung (11.891 ng/g), followed by liver (10.110 ng/g), kidney (10.095 ng/g), heart (4.251 ng/g), testis (3.750 ng/g), stomach (3.182 ng/g), adipose tissue (1.116 ng/g) and brain (0.982 ng/ml) in 3h after multiple oral dosing of 200mg Gemifloxacin mesylate for 7 days. This method may also be used for gemifloxacin tissue distribution modeling study in rat tissues and antibiotic residue analyses in other animal tissues.
Gemifloxacin mesylate (GFM) stability evaluation applying a validated bioassay method and in vitro cytotoxic study
Talanta 2011 Feb 15;83(5):1774-9.PMID:21238783DOI:10.1016/j.talanta.2010.11.069.
The validation of a microbiological assay applying the cylinder-plate method to determine the quinolone Gemifloxacin mesylate (GFM) content is described. Using a strain of Staphylococcus epidermidis ATCC 12228 as the test organism, the GFM content in tablets at concentrations ranging from 0.5 to 4.5 μg mL(-1) could be determined. A standard curve was obtained by plotting three values derived from the diameters of the growth inhibition zone. A prospective validation showed that the method developed is linear (r=0.9966), precise (repeatability and intermediate precision), accurate (100.63%), specific and robust. GFM solutions (from the drug product) exposed to direct UVA radiation (352 nm), alkaline hydrolysis, acid hydrolysis, thermal stress, hydrogen peroxide causing oxidation, and a synthetic impurity were used to evaluate the specificity of the bioassay. The bioassay and the previously validated high performance liquid chromatographic (HPLC) method were compared using Student's t test, which indicated that there was no statistically significant difference between these two validated methods. These studies demonstrate the validity of the proposed bioassay, which allows reliable quantification of GFM in tablets and can be used as a useful alternative methodology for GFM analysis in stability studies and routine quality control. The GFM reference standard (RS), photodegraded GFM RS, and synthetic impurity samples were also studied in order to determine the preliminary in vitro cytotoxicity to peripheral blood mononuclear cells. The results indicated that the GFM RS and photodegraded GFM RS were potentially more cytotoxic than the synthetic impurity under the conditions of analysis applied.